NO20006560D0 - Apomorfinholdige doseringsformer for forbedring av erektil dysfunksjon hos menn - Google Patents

Apomorfinholdige doseringsformer for forbedring av erektil dysfunksjon hos menn

Info

Publication number
NO20006560D0
NO20006560D0 NO20006560A NO20006560A NO20006560D0 NO 20006560 D0 NO20006560 D0 NO 20006560D0 NO 20006560 A NO20006560 A NO 20006560A NO 20006560 A NO20006560 A NO 20006560A NO 20006560 D0 NO20006560 D0 NO 20006560D0
Authority
NO
Norway
Prior art keywords
apomorphine
men
dosage forms
erectile dysfunction
containing dosage
Prior art date
Application number
NO20006560A
Other languages
English (en)
Other versions
NO20006560L (no
Inventor
Ragab El-Rashidy
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of NO20006560D0 publication Critical patent/NO20006560D0/no
Publication of NO20006560L publication Critical patent/NO20006560L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20006560A 1998-06-22 2000-12-21 Apomorfinholdige doseringsformer for forbedring av erektil dysfunksjon hos menn NO20006560L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,406 US6121276A (en) 1994-04-22 1998-06-22 Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
PCT/US1999/014053 WO1999066916A1 (en) 1998-06-22 1999-06-22 Apomorphine-containing dosage forms for ameliorating male erectile dysfunction

Publications (2)

Publication Number Publication Date
NO20006560D0 true NO20006560D0 (no) 2000-12-21
NO20006560L NO20006560L (no) 2001-02-22

Family

ID=22289678

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006560A NO20006560L (no) 1998-06-22 2000-12-21 Apomorfinholdige doseringsformer for forbedring av erektil dysfunksjon hos menn

Country Status (17)

Country Link
US (2) US6121276A (no)
EP (1) EP1094799B1 (no)
JP (1) JP2002518439A (no)
CN (1) CN1201738C (no)
AT (1) ATE336234T1 (no)
AU (1) AU776686B2 (no)
BR (1) BR9911408A (no)
CA (1) CA2336095A1 (no)
DE (1) DE69932823T2 (no)
HK (1) HK1040179A1 (no)
HU (1) HUP0102834A3 (no)
IL (1) IL140272A (no)
MX (1) MXPA00012620A (no)
NO (1) NO20006560L (no)
NZ (1) NZ509438A (no)
PL (1) PL195119B1 (no)
WO (1) WO1999066916A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
AR032556A1 (es) * 2001-02-08 2003-11-12 Pharmacia Corp Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
DE60308647T2 (de) * 2002-02-07 2007-08-09 Pharmacia Corp. Pharmazeutische darreichungsform zur mukosalen verabreichung
US20030220292A1 (en) * 2002-02-15 2003-11-27 Nexmed (Holdings), Inc. Treatment of erectile dysfunction
AU2003223304A1 (en) * 2002-03-19 2003-10-08 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
ES2487415T3 (es) 2003-03-17 2014-08-20 Neurohealing Pharmaceuticals, Inc. Tratamiento dopaminérgico de alta potencia de deficiencias neurológicas asociadas con lesiones cerebrales
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
CA2605993A1 (en) * 2005-04-25 2006-11-02 Ellen Eatough Mind-body learning system and methods of use
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
DE102007008853A1 (de) 2007-02-23 2008-08-28 Plath Gmbh System und Verfahren zur Feststellung der Existenz eines Täuschfelds
KR20110075044A (ko) 2007-04-02 2011-07-05 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) * 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 渇望入力及び支援システム
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US20180280465A1 (en) 2015-09-28 2018-10-04 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3885034A (en) * 1955-09-07 1975-05-20 Bayer Ag Phenothiazine derivatives in the treatment of psychotic persons
US3976780A (en) * 1968-07-29 1976-08-24 Societe D'etudes Scientifiques Et Industrielles L'ile-De-France Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
AU1508183A (en) * 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US5011992A (en) * 1984-06-28 1991-04-30 Bristol-Myers Squibb Company Pharmacologically active substituted benzamides
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
US4772459A (en) * 1986-09-09 1988-09-20 Erbamont, Inc. Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4857553A (en) * 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DK0865789T3 (da) * 1993-03-26 2005-07-18 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af dihydroergotamin
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
KR100374924B1 (ko) * 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
JP3962108B2 (ja) * 1995-04-03 2007-08-22 中外製薬株式会社 スクラルファート含有製剤組成物
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction

Also Published As

Publication number Publication date
PL195119B1 (pl) 2007-08-31
BR9911408A (pt) 2001-12-04
AU776686B2 (en) 2004-09-16
IL140272A (en) 2007-07-04
DE69932823T2 (de) 2007-03-15
CN1201738C (zh) 2005-05-18
WO1999066916A1 (en) 1999-12-29
EP1094799A4 (en) 2002-05-08
NZ509438A (en) 2003-06-30
IL140272A0 (en) 2002-02-10
EP1094799A1 (en) 2001-05-02
DE69932823D1 (de) 2006-09-28
JP2002518439A (ja) 2002-06-25
NO20006560L (no) 2001-02-22
MXPA00012620A (es) 2005-11-08
HUP0102834A2 (hu) 2002-07-29
EP1094799B1 (en) 2006-08-16
CA2336095A1 (en) 1999-12-29
CN1313762A (zh) 2001-09-19
PL345401A1 (en) 2001-12-17
HK1040179A1 (en) 2002-05-31
US6121276A (en) 2000-09-19
HUP0102834A3 (en) 2002-10-28
AU4705899A (en) 2000-01-10
US6306437B1 (en) 2001-10-23
ATE336234T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
NO20006560D0 (no) Apomorfinholdige doseringsformer for forbedring av erektil dysfunksjon hos menn
AR033342A1 (es) Una composicion otica topica o intranasal para tratar el dolor otico y el uso topico de agonistas de opioides kapa para tratar el dolor otico
DE60112102D1 (de) Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen
CA2188385A1 (en) Dosage Forms and Method for Ameliorating Male Erectile Dysfunction
AU5984701A (en) Method of treating immune pathologies with low dose estrogen
GR3032251T3 (en) Compositions containing prostaglandin e1 and/or troxerutine complexed with phosphatidylcholine for topical treatment of erectile impotence
NZ599847A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
HK1030133A1 (en) Composition and method for treating penile erectile dysfunction
DE60113290D1 (de) Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
WO2006036634A3 (en) Systemic administration of therapeutic amino acids and n-acetylamino acids
GB0031302D0 (en) Napthalene derivatives
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
YU53402A (sh) Preparat
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
SE9900025D0 (sv) Method and composition for treatment of female sexual dysfunction
PT721467E (pt) Utilizacao de relaxina como analgesico e paliativo para dor refractaria
KR960003728A (ko) 포유류의 허파 모세관 누출을 감소시키는 방법
DK1150683T3 (da) Anvendelse af dienogest i højere dosering
MXPA03003481A (es) Tratamiento de disfuncion sexual utilizando antagonista de bombesina.
MA38848A1 (fr) Anticorps anti-prlr et utilisations associées
UY26747A1 (es) Formas de dosificacion y metodos para mejorar la disfuncion erectil masculina
MX9604981A (es) Formas de dosis y metodo para aliviar las disfunciones erectiles masculinas.
HK1036594A1 (en) Formulations for the transdermal administration offenoldopam.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application